Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Cash from Financing Activities (2016 - 2025)

Voyager Therapeutics' Cash from Financing Activities history spans 11 years, with the latest figure at $136000.0 for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 76.31% year-over-year to $136000.0; the TTM value through Dec 2025 reached $816000.0, down 99.28%, while the annual FY2025 figure was $816000.0, 99.28% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was $136000.0 at Voyager Therapeutics, up from $85000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $112.9 million in Q1 2024 and bottomed at $12000.0 in Q1 2022.
  • The 5-year median for Cash from Financing Activities is $331000.0 (2023), against an average of $7.9 million.
  • The largest annual shift saw Cash from Financing Activities surged 260783.33% in 2023 before it plummeted 99.93% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at $227000.0 in 2021, then grew by 21.59% to $276000.0 in 2022, then surged by 66.67% to $460000.0 in 2023, then rose by 24.78% to $574000.0 in 2024, then tumbled by 76.31% to $136000.0 in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Cash from Financing Activities are $136000.0 (Q4 2025), $85000.0 (Q3 2025), and $513000.0 (Q2 2025).